Progress and novel discoveries in biliary tract diseases

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 1, 1999, Pages 47-50

  Vleggaar, Frank P ^a   Van Berge Henegouwen, Gerard P ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; PREDNISOLONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

BILIARY TRACT DISEASE; CHOLESTASIS; CHOLESTEROL STONE; HUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SHORT SURVEY; SYNDROME;

EID: 0033013709     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199901000-00010     Document Type: Short Survey

References (38)

1. Neuberger J. Primary biliary cirrhosis. Lancet 1997; 350:875-879.
2. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci 1985; 30:642-649.
3. Güldütuna S, Zimmer G, Imhof M, Bhatti M, Tjangeng Y, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104:1736-1744.
4. Heuman DM, Bajaj RS, Lin Q. Absorption of mixtures of bile salt taurine conjugates to lecithine cholesterol membranes: implications for bile sait toxicity and cytoprotection. J Lipid Res 1996; 37:562-573.
5. Van de Heijning BJM, van de Broek AM, van Berge-Henegouwen GP. Membrane cholesterol content of cholesterol/phospholipid vesicles determines the susceptibility to both damage and protection by bile salts. Eur J Gastroenteml Hepatol 1997; 9:473-479.
6. Poupon RE, Poupon R, Balkau B and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330:1342-1347.
7. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19:1149-1156.
8. Combes B, Carithers R Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-766.
9. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110:1515-1518.
10. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
11. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 348:1399-1402.
12. Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 1996; 25:49-57.
13. Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, vanBerge-Henegouwen GP, ten Kate FJW, vandenHoek E, et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis - a 1-year randomized placebo-controlled study. J Hepatol 1998; 29:736-742.
14. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924-933.
15. Lindor KD. Ursodioi for primary sclerosing cholangitis. N Engl J Med 1997; 336:691-695.
16. Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90:455-459.
17. Loftus E Jr, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, Melton L. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996; 110:1496-1502.
18. van Erpecum KJ, Smits SJ, van de Meeberg PC, Linn FH, Wolfhagen FH, van Berge-Henegouwen GP, Algra A. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996; 110:1503-1506.
19. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113:1264-1269.
20. Portincasa P, van de Meeberg P, van Erpecum KJ, Palasciano G, van Berge-Henegouwen GP. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenteml 1997; 32(suppl 223):60-69.
21. Juvonen T, Kervinen K, Kairaluoma Ml, Lajunen LH, Kesaniemi YA. Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology 1993; 104:1806-1813.
22. Wang DQ, Carey MC. Complete mapping of crystallization pathways during cholesterol precipitation from model bile: influence of physical-chemical variables of pathophysiologic significance and identification of a stable liquid-crystalline state in cold, dilute and hydrophilic bile salt-containing systems. J Lipid Res 1996; 37:606-630.
23. Pellegrini CA, Ryan T, Broderick W, Way LW. Gallbladder filling and emptying during cholesterol gallstone formation in the prairie dog. A cholescintigraphic study. Gastroenterology 1986; 90:143-149.
24. Van der Werf SD, van Berge-Henegouwen GP, Palsma DM, Ruben AT. Motor function of the gallbladder and cholesterol saturation of duodenal bile. Neth J Med 1987; 30:160-171.
25. Xu QW, Shaffer EA. The potential site of impaired gallbladder contractility in an animal model of cholesterol gallstone disease. Gastroenterology 1996; 110:251-257.
26. Xu QW, Shaffer EA. The influence of bile salts on small intestinal motility in the guinea pig in vitro. Gastroenterology 1992; 103:29-35.
27. Heaton KW, Emmett PM, Symes CL, Braddon FEM. An explanation for gallstones in normal-weight women: slow intestinal transit. Lancet 1993; 341:8-10.
28. Van Erpecum KJ, van Berge-Henegouwen GP. Gallstones, an intestinal disease? Gut, in press.
29. Shoda J, He B, Tanaka N, Matsuzaki Y, Osuga T, Yamamori S, et al. Increase of deoxycholate in supersaturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder emptying and small intestinal transit Hepatology 1995; 21:1291-1302.
30. Jazrawi RP, Pazzi P, Petroni ML, Prandini N, Paul C, Adam JA, Northfield TC. Postprandial gallbladder motor function: refilling and turnover of bile in health and cholelithiasis. Gastmenterology 1995; 109:582-591.
31. Hussaini SH, Murphy GM, Kennedy C, Besser GM, Wass JAH, Dowling RH. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastmenterology 1994; 107:1503-1513.
32. Veysey MJ, Gathercole DJ, Mallet A. Large bowel transit time influences deoxycholic acid input rate and pool size - risk factors for octreotide-induced gallstones [Abstract]. Gastmenterology 1997; 112:A525.
33. Xu QW, Scott RB, Tan DTM, Shaffer EA. Slow intestinal transit: a motor disorder contributing to cholesterol gallstone formation in the ground squirrel. Hepatology 1996; 23:1664-1672.
34. Bull LN, Carlton VE, Stricker NL, Baharloo S, Deyoung JA, Freimer NB, et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome) - evidence for heterogeneity. Hepatology 1997; 26:155-164.
35. Houwen RHJ, Baharloo S, Blankenship K, Raeymakers P, Juijn JA, Sandkuijl LA, et al. Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis. Nature Genet 1994; 8:380-386.
36. Oude Elferink PJ, van Berge-Henegouwen GP. Cracking the genetic code for benign recurrent and progressive familial intrahepatic cholestasis. J Hepatol 1998; 29:317-320.
37. Strautnieks SS, Kagalwalla AF, Tanner MS, Knisely AS, Bull LN, Freimer NB, et al. Identification of a locus for progressive familial intra-hepatic cholestasis on chromosome 2q24. Am J Hum Genet 1997; 61:630-633.
38. De Vree JML, Jaquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the mdr3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998; 95:282-287.